Adherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of Nonalcoholic Fatty Liver Disease

References

• Askari F, Rashidkhani B, Hekmatdoost A. 2014. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 34:143–148.
   PubMed Web of Science ®Google Scholar
• Barnes TL, Crandell JL, Bell RA, Mayer-Davis EJ, Dabelea D, Liese AD. 2013. Change in DASH diet score and cardiovascular risk factors in youth with type 1 and type 2 diabetes mellitus: the SEARCH for Diabetes in Youth Study. Nutr Diabetes. 3:e91.
   PubMed Web of Science ®Google Scholar
• Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhouser ML, Tinker LF, Van Horn L, Waring ME, Li W, Shikany JM, Eaton CB. 2014. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. Am J Clin Nutr. 99:344–351.
   PubMed Web of Science ®Google Scholar
• Collison KS, Maqbool Z, Saleh SM, Inglis A, Makhoul NJ, Bakheet R, Al-Johi M, Al-Rabiah R, Zaidi MZ, Al-Mohanna FA. 2009. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J Lipid Res. 50:1521–1537.
   PubMed Web of Science ®Google Scholar
• Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JP. 2014. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet. 114:1181–1194.
   PubMed Web of Science ®Google Scholar
• Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K. 2010. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 299:E685–E694.
   PubMed Web of Science ®Google Scholar
• Esfahani FH, Asghari G, Mirmiran P, Azizi F. 2010. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. J Epidemiol. 20:150–158.
   PubMed Web of Science ®Google Scholar
• Eslamparast T, Eghtesad S, Hekmatdoost A, Poustchi H. 2013. Probiotics and nonalcoholic fatty liver disease. Middle East J Dig Dis. 5:129–136.
   PubMedGoogle Scholar
• Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. 2015. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 7:204–212.
   PubMedGoogle Scholar
• Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. 2014a. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 99:535–542.
   PubMed Web of Science ®Google Scholar
• Eslamparast T, Zamani F, Hekmatdoost A, Sharafkhah M, Eghtesad S, Malekzadeh R, Poustchi H. 2014b. Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br J Nutr. 112:438–445.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh F, Adibi P, Hekmatdoost A. 2015. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 114:796–803.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. 2014. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 34:837–843.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, Chiuve SE, Buring JE, Ridker PM, Glynn RJ. 2012. Comparison of associations of adherence to a Dietary Approaches to Stop Hypertension (DASH)-style diet with risks of cardiovascular disease and venous thromboembolism. J Thromb Haemost. 10:189–198.
   PubMed Web of Science ®Google Scholar
• Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. 2008. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med. 168:713–720.
   PubMed Web of Science ®Google Scholar
• Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, Homayounfar R, Fakheri H. 2013. How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon. 13:e15227.
   PubMed Web of Science ®Google Scholar
• Ghorbani Z, Hekmatdoost A, Mirmiran P. 2014. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab. 12:e18081.
   PubMedGoogle Scholar
• Gupta V, Mah XJ, Garcia MC, Antonypillai C, van der Poorten D. 2015. Oily fish, coffee and walnuts: dietary treatment for nonalcoholic fatty liver disease. World J Gastroenterol. 21:10621–10635.
   PubMed Web of Science ®Google Scholar
• Kelishadi R, Rabiee K, Khosravi A, Famouri F, Sadeghi M, Rouhafza H, Shirani Sh. 2001. Assessment of physical activity of adolescents in Isfahan. Shahrekord Univ Med Sci J. 3:55–66.
   Google Scholar
• Liese AD, Bortsov A, Gunther AL, Dabelea D, Reynolds K, Standiford DA, Liu L, Williams DE, Mayer-Davis EJ, D'Agostino RB Jr, Bell R, Marcovina S. 2011. Association of DASH diet with cardiovascular risk factors in youth with diabetes mellitus: the SEARCH for Diabetes in Youth study. Circulation. 123:1410–1417.
   PubMed Web of Science ®Google Scholar
• Liese AD, Nichols M, Sun X, D’Agostino RB Jr., Haffner SM. 2009. Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care. 32:1434–1436.
   PubMed Web of Science ®Google Scholar
• Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. 2014. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 97:7386–7393.
   PubMed Web of Science ®Google Scholar
• Oddy WH, Herbison CE, Jacoby P, Ambrosini GL, O’Sullivan TA, Ayonrinde OT, Olynyk JK, Black LJ, Beilin LJ, Mori TA, Hands BP, Adams LA. 2013. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol. 108:778–785.
   PubMed Web of Science ®Google Scholar
• Rahimlou M, Ahmadnia H, Hekmatdoost A. 2015. Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future. World J Hepatol. 7:2597–2602.
   PubMed Web of Science ®Google Scholar
• Rinella ME. 2015. Nonalcoholic fatty liver disease: a systematic review. JAMA. 313:2263–2273.
   PubMed Web of Science ®Google Scholar
• Ross AB, Godin JP, Minehira K, Kirwan JP. 2013. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol. 2013:585876
   PubMed Web of Science ®Google Scholar
• Salomone F, Godos J, Zelber-Sagi S. 2016. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver Int. 36:5–20.
   PubMed Web of Science ®Google Scholar
• Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB. 2004. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 292:927–934.
   PubMed Web of Science ®Google Scholar
• Struijk EA, May AM, Wezenbeek NL, Fransen HP, Soedamah-Muthu SS, Geelen A, Boer JM, van der Schouw YT, Bueno-de-Mesquita HB, Beulens JW. 2014. Adherence to dietary guidelines and cardiovascular disease risk in the EPIC-NL cohort. Int J Cardiol. 176:354–359.
   PubMed Web of Science ®Google Scholar
• Vogt TM, Appel LJ, Obarzanek E, Moore TJ, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Cutler JA, Windhauser MM, Lin PH, Karanja NM. 1999. Dietary Approaches to Stop Hypertension: rationale, design, and methods. DASH Collaborative Research Group. J Am Diet Assoc. 99:S12–S18.
   PubMedGoogle Scholar
• Wijarnpreecha K, Thongprayoon C, Edmonds PJ, Cheungpasitporn W. 2016. Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: a systematic review and meta-analysis. QJM. 109:461–466.
   PubMed Web of Science ®Google Scholar
• Willett W. 2012. Nutritional epidemiology. New York: Oxford University Press.
   Google Scholar
• Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A. 2016. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 67:461–469.
   PubMed Web of Science ®Google Scholar
• Zivkovic AM, German JB, Sanyal AJ. 2007. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 86:285–300.
   PubMed Web of Science ®Google Scholar